PEG-MGF: Dosage, Benefits & Side Effects
By Peptide Assistant Editorial Team · · · 6 sources cited
Overview
PEG-MGF (PEGylated Mechano Growth Factor) is a PEGylated version of the MGF splice variant of IGF-1 (IGF-1Ec in humans). Polyethylene glycol (PEG) is attached to slow its breakdown, though no published study reports the half-life of PEG-MGF. The MGF splice variant is expressed in muscle in response to mechanical stress and its appearance tracks satellite cell activation, but the MGF peptide itself has never been isolated from cells or tissue.
Mechanism of Action
MGF is a splice variant of the IGF-1 gene produced specifically in mechanically stressed skeletal muscle and cardiac tissue. While standard IGF-1 splice variants activate the IGF-1 receptor for general growth signaling, MGF has a unique E-domain that preferentially activates muscle satellite cells — the resident stem cells of skeletal muscle. Upon satellite cell activation, these quiescent cells enter the cell cycle, proliferate, and differentiate into new myonuclei that fuse with existing muscle fibers, increasing their capacity for protein synthesis and growth. The PEGylation is intended to shield MGF from rapid proteolytic degradation. No published study has measured the half-life of MGF or of PEG-MGF in any species, so the 5 to 7 minute and several-hour half-lives often quoted for them have no published source.
PEG-MGF Benefits: What the Research Shows
- Hill and Goldspink (2003) in the Journal of Physiology demonstrated in rat muscle that MGF is the first IGF-1 splice variant expressed after mechanical damage, with IGF-IEa rising later as MGF declined
- Yang and Goldspink (2002) showed in cell culture that the E domain of MGF increased myoblast proliferation and held back differentiation, unlike mature IGF-1, and that it acts through a receptor other than the IGF-1 receptor
- Research in FEBS Letters showed that older rat muscle expressed much less MGF after mechanical overload and failed to upregulate the IGF-1 receptor and MyoD
PEG-MGF Dosage
- Standard dose: 200–400 mcg subcutaneous or intramuscular injection, 2–3 times per week
- Post-workout dosing: inject within 30 minutes of resistance training for maximal satellite cell activation
- Bilateral localized protocol: some users inject directly into trained muscle groups for targeted effects
- Cycle: 4–6 weeks on, 4 weeks off
- Often stacked with IGF-1 LR3 on non-training days and PEG-MGF on training days
- Do not mix PEG-MGF and IGF-1 LR3 in the same injection — they compete for binding sites
Disclaimer: Dosing information is compiled from research literature and community protocols for educational purposes only. This is not medical advice. Always consult a qualified healthcare provider before starting any peptide protocol.
PEG-MGF Side Effects & Safety
Known Side Effects
- Injection site pain and swelling — particularly with intramuscular injection, can be significant
- Hypoglycemia — potential glucose-lowering effects through IGF-1 pathway activation
- Localized muscle soreness — some users report increased DOMS-like symptoms in injected muscles
- Water retention — mild, typically during the first 1–2 weeks
- Theoretical long-term risk of promoting growth in unintended tissues, though not observed in published research
Safety Profile
PEG-MGF is a research compound without human clinical trials. Safety information is extrapolated from preclinical studies and the broader IGF-1 literature. The PEGylation is generally safe — PEG is widely used in pharmaceutical formulations. The primary theoretical concern is systemic growth factor activity, though MGF's preferential action on satellite cells suggests more targeted effects than systemic IGF-1. Individuals with a history of cancer should avoid growth factor peptides. Monitor blood glucose during use, particularly if diabetic or using insulin.
What to Expect
Week 1–2: Enhanced post-workout pump and increased muscle fullness. Some users report faster recovery between training sessions. Mild water retention possible. Weeks 3–4: Noticeable improvements in muscle recovery and growth. Training volume capacity increases as satellite cells become activated and contribute to repair. Weeks 5–6: Peak muscle-building effects. Users report improved body composition, increased muscle density, and enhanced ability to maintain training intensity. No human study of PEG-MGF has been published, so none of this has been measured in people.
Common Stacks
IGF-1 LR3
IGF-1 LR3 drives muscle protein synthesis and differentiation while PEG-MGF activates satellite cell proliferation — sequential use targets different phases of muscle growth
BPC-157
BPC-157 promotes tendon, ligament, and tissue healing that supports the increased muscle recovery demands created by PEG-MGF's satellite cell activation
Ipamorelin
Ipamorelin stimulates endogenous GH release which drives systemic IGF-1 production, complementing PEG-MGF's localized satellite cell activation
Storage & Handling
Store lyophilized PEG-MGF at -20°C for long-term storage (up to 12 months) or 2–8°C for up to 3 months. Reconstitute with bacteriostatic water — typically 1 mL per vial. After reconstitution, refrigerate and use within 3–4 weeks. PEGylated peptides are more stable than their non-PEGylated counterparts but still require cold chain storage. Do not freeze reconstituted solution.
Pricing & Available Variants
Prices sourced from peptides.gg marketplace. Prices may vary.
References
- Hill M, Goldspink G. Expression and splicing of the insulin-like growth factor gene in rodent muscle is associated with muscle satellite (stem) cell activation following local tissue damage. J Physiol. 2003.
- Yang SY, Goldspink G. Different roles of the IGF-I Ec peptide (MGF) and mature IGF-I in myoblast proliferation and differentiation. FEBS Lett. 2002.
- Matheny RW Jr, Nindl BC, Adamo ML. Minireview: Mechano-growth factor: a putative product of IGF-I gene expression involved in tissue repair and regeneration. Endocrinology. 2010.
- Owino V, Yang SY, Goldspink G. Age-related loss of skeletal muscle function and the inability to express the autocrine form of insulin-like growth factor-1 (MGF) in response to mechanical overload. FEBS Lett. 2001.
- Dominikowski A, Rękoś Z, Olejarz M, et al. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. Front Endocrinol (Lausanne). 2026.
- The Prohibited List 2026, section S2.3 Growth factors and growth factor modulators. World Anti-Doping Agency. 2026.
Related Peptides
Track PEG-MGF in Your Protocol
Log your PEG-MGF doses, track consistency, and monitor your protocol with Peptide Assistant — completely free.
Start Tracking Free